BHV-8000, DaTSCAN 74 MBq/ml solution for injection, DaTSCAN 74 MBq/ml solution for injection, BHV-8000, Placebo for BHV-8000 clinical trials

A Phase 2/3, Double-Blind, Placebo-Controlled Study of BHV-8000 in Participants with Early Parkinson’s Disease

This study is testing a new drug, BHV-8000, for people with early Parkinson's disease. Researchers want to see if it can slow down the worsening of daily symptoms compared to a dummy drug (placebo).